B
Bull
Bull · 25%NRXS
$3.72
Precio del escenario
$6.000
-0.020 (-0.33%)Al cierre
Loading chart…
- High
- 6.105
- Open
- 6.060
- VWAP
- 6.02
- Vol
- 40.21K
- Mkt Cap
- 17.68M
- Low
- 5.940
- Amount
- 241.85K
- EV/EBITDA, TTM
- -3.11
Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies for chronic and debilitating conditions in gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. Its IB-Stim, is a Percutaneous Electrical Nerve Field Stimulation (PENFS) technology intended to be used in patients eight years and older with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. Its second product, RED (Rectal Expulsion Device), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge to defecate at lower volumes of distension.
AI analysis of Neuraxis Inc (NRXS)
buyNeuraxis Inc (NRXS) is a good buy right now, primarily due to its significant revenue growth of 116% year-over-year in Q2 2026, reaching $1.9 million, and a gross margin of 86.42%, indicating strong profitability potential. However, the main risk is the current RSI of 30.094, suggesting the stock is oversold and may face short-term volatility.
Métricas de valoración
The current forward P/E ratio for Neuraxis Inc (NRXS) is 0.00, compared to its 5-year average forward P/E of -17.02.
Alphio AI Price Scenarios for NRXS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
2.008-12NASDAQ.COMNeurAxis (NRXS) Q2 2026 Earnings Call Transcript
9.508-11NASDAQ.COMNeurAxis Reports Strong Q2 Growth Driven by CPT Code Expansion
9.505-12seekingalphaNeurAxis Q1 2026 Earnings Call Insights
- 9.505-12seekingalpha
NeurAxis Reports Q1 Revenue of $1.6M
9.505-12NewsfilterNeurAxis Reports 80% Revenue Growth in Q1 2026
NRXS FAQ — answered by Alphio AI
Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies for chronic and debilitating conditions in gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. Its IB-Stim, is a Percutaneous Electrical Nerve Field Stimulation (PENFS) technology intended to be used in patients eight years and older with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. Its second product, RED (Rectal Expulsion Device), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge to defecate at lower volumes of distension. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).
Neuraxis Inc (NRXS) is a good buy right now, primarily due to its significant revenue growth of 116% year-over-year in Q2 2026, reaching $1.9 million, and a gross margin of 86.42%, indicating strong profitability potential. However, the main risk is the current RSI of 30.094, suggesting the stock is oversold and may face short-term volatility.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.